Theratechnologies Inc. (TO:TH) — Market Cap & Net Worth
Market Cap & Net Worth: Theratechnologies Inc. (TH)
Theratechnologies Inc. (TO:TH) has a market capitalization of $148.68 Million (CA$205.53 Million) as of May 4, 2026. Listed on the TO stock exchange, this Canada-based company holds position #17674 globally and #568 in its home market, demonstrating a -1.76% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theratechnologies Inc.'s stock price CA$4.47 by its total outstanding shares 45980019 (45.98 Million). Analyse how efficiently does Theratechnologies Inc. generate cash to see how efficiently the company converts income to cash.
Theratechnologies Inc. Market Cap History: 2015 to 2025
Theratechnologies Inc.'s market capitalization history from 2015 to 2025. Data shows change from $252.79 Million to $148.68 Million (-4.99% CAGR).
Theratechnologies Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theratechnologies Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.01x
Theratechnologies Inc.'s market cap is 1.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $252.79 Million | $22.48 Million | $1.17 Million | 11.25x | 215.15x |
| 2016 | $364.54 Million | $27.59 Million | $305.16K | 13.21x | 1194.59x |
| 2017 | $955.26 Million | $33.31 Million | -$14.34 Million | 28.68x | N/A |
| 2018 | $1.11 Billion | $44.10 Million | -$4.53 Million | 25.10x | N/A |
| 2019 | $566.77 Million | $63.22 Million | -$17.49 Million | 8.97x | N/A |
| 2020 | $424.41 Million | $66.05 Million | -$22.67 Million | 6.43x | N/A |
| 2021 | $508.23 Million | $69.82 Million | -$31.73 Million | 7.28x | N/A |
| 2022 | $159.65 Million | $80.06 Million | -$47.24 Million | 1.99x | N/A |
| 2023 | $71.18 Million | $81.76 Million | -$23.96 Million | 0.87x | N/A |
| 2024 | $87.14 Million | $85.87 Million | -$8.31 Million | 1.01x | N/A |
Competitor Companies of TH by Market Capitalization
Companies near Theratechnologies Inc. in the global market cap rankings as of May 4, 2026.
Key companies related to Theratechnologies Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Theratechnologies Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, Theratechnologies Inc.'s market cap moved from $252.79 Million to $ 148.68 Million, with a yearly change of -4.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | CA$148.68 Million | +70.61% |
| 2024 | CA$87.14 Million | +22.43% |
| 2023 | CA$71.18 Million | -55.42% |
| 2022 | CA$159.65 Million | -68.59% |
| 2021 | CA$508.23 Million | +19.75% |
| 2020 | CA$424.41 Million | -25.12% |
| 2019 | CA$566.77 Million | -48.80% |
| 2018 | CA$1.11 Billion | +15.88% |
| 2017 | CA$955.26 Million | +162.04% |
| 2016 | CA$364.54 Million | +44.21% |
| 2015 | CA$252.79 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Theratechnologies Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $148.68 Million USD |
| MoneyControl | $148.68 Million USD |
| MarketWatch | $148.68 Million USD |
| marketcap.company | $148.68 Million USD |
| Reuters | $148.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Theratechnologies Inc.
Theratechnologies Inc., a biopharmaceutical company, focuses on the commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatm… Read more